Johnson & Johnson Publishes Interim Results of Single-Shot COVID-19 Vaccine in P-I/IIa Sub-Study for COVID 19 in NEJM
Shots:
- The ongoing P-I/IIa sub-study involves evaluating safety- reactogenicity & immunogenicity of COVID-19 vaccine (IM- given as single-dose or two-dose- 8 wks. apart) in adults across multiple clinical sites in Belgium & the US
- The results demonstrated durable humoral & cellular immune responses in single-shot COVID-19 vaccine @8mos. after immunization & elicits neutralizing Ab activity against Delta variant (B.1.617.2) & other SARS-CoV-2 variants of concern
- The results from a new analysis of blood samples in the P-III ENSEMBLE study showed that the single-shot COVID-19 vaccine- induced neutralizing Ab activity against the Delta variant at a higher level
Ref: J&J | Image: Actualidad RT
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com